Effects of Aerobic Exercise on Neurocognitive Function in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer: The Exercise Program in Cancer and Cognition Randomized Controlled Trial
Overview
Psychology
Authors
Affiliations
Objective: The Exercise Program in Cancer and Cognition (EPICC) Study was a randomized controlled trial (RCT) designed to determine whether six months of moderate-intensity aerobic exercise improves neurocognitive function in women with breast cancer (BC) receiving endocrine therapy (ET).
Methods: Postmenopausal women with hormone receptor+, early-stage BC, within two years post-primary therapy were randomized to the exercise intervention (six months, ≥150 minutes of moderate-intensity aerobic exercise/week) or usual care control condition. Outcomes were assessed at pre-randomization and after intervention completion. Groups were compared using linear mixed-effects modeling.
Results: Participants (N=153) were years old, with stage I BC (64.1%) and a median of 4.7 months post-diagnosis. We found a group-by-time interaction (p=0.041) and a trend for the main effect of time (p=0.11) for processing speed with improved performance in the exercise group and no change in the controls. Similar main effects of time were observed for learning and memory (p=0.024) and working memory (p=0.01). Better intervention adherence was associated with improved processing speed (p=0.017).
Conclusions: Six months of moderate-intensity aerobic exercise improves processing speed in postmenopausal women with BC receiving ET who initiate exercise within two years of completing primary therapy (surgery +/- chemotherapy). This is the first large-scale study to examine the effects of aerobic exercise on neurocognitive function in women with BC. Additional research is needed to address the long-term effects of aerobic exercise on cognitive function.
Molina-Hidalgo C, Wan L, Velazquez-Diaz D, Huang H, Grove G, Bender C Front Hum Neurosci. 2024; 18:1443916.
PMID: 39507060 PMC: 11538074. DOI: 10.3389/fnhum.2024.1443916.
Hartman S, Zablocki R, Tam R, Palmer B, Parker B, Sears D Front Cognit. 2024; 3.
PMID: 39483324 PMC: 11526472. DOI: 10.3389/fcogn.2024.1332960.
Role function in postmenopausal women during aromatase inhibitor therapy for breast cancer.
Melnyk H, Dickson V, Bender C, Yu G, Djukic M, Merriman J J Cancer Surviv. 2024; .
PMID: 39425854 DOI: 10.1007/s11764-024-01697-x.
Janelsins M, Van Dyk K, Hartman S, Koll T, Cramer C, Lesser G J Natl Cancer Inst. 2024; 117(2):217-228.
PMID: 39250738 PMC: 11807440. DOI: 10.1093/jnci/djae209.